EN DE
Watch Hangzhou Jiuyuan Gene for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hangzhou Jiuyuan Gene (2566) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Hangzhou Jiuyuan Gene stock HK$9.90, price HK$4.26, upside +132.4%, quality 60 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

HJ Hangzhou Jiuyuan Gene logo Thin data Nov 14, 2026

Hangzhou Jiuyuan Gene

2566 · HK

Cheap (57% below fair value) and solid company, but falling price: meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$9.90 · Strongly undervalued 
Quality 60/100 
Solidly profitable · 10.7% net margin (TTM) 
Low debt 
Generates free cash flow 
1.6% dividend yield · Well covered
Ranks above peers (13/14) 
Even on cautious assumptions the value is 81% above the price (HK$7.73). 
Mixed Growth (revenue 3y +5.1 %/yr in CNY) 
Moderate moat 52/100 · thin data
Falling price (downtrend) 
Thin data 
Watch Hangzhou Jiuyuan Gene for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$15.62 HK$4.26 Fair Value HK$9.90 Nov 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

23‑month range HK$4.26 – HK$15.62 · fair‑value band HK$7.73 – HK$11.96 · the HK$4.26 price screens below the HK$9.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Hangzhou Jiuyuan Gene in your weekly email

Every Wednesday you see whether Hangzhou Jiuyuan Gene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally.

Show moreShow less

The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-G"CSF injection.

It also provides Jilixin avatrombopag maleate tablets; Jipailin, a low molecular weight heparin sodium injection; and Yinuojia, an enoxaparin sodium injection.

The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.

Stock analysis

Hangzhou Jiuyuan Gene (2566) currently trades at HK$4.26, while our model-based Fair Value estimate is HK$9.90, implying the stock looks roughly 57% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of HK$14.04 per share, and 22 of the 24 models we run sit above the HK$4.26 price.

Bear case: the Asset-Based group reads lowest at HK$5.02, and 2 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$7.73 (bear) to HK$11.96 (bull), the price of HK$4.26 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Hangzhou Jiuyuan Gene reported revenue of 1.3B CNY in FY2025 versus 1.3B CNY in FY2021, a compound 0.0%/yr. Reported net income was 138M CNY in FY2025, compounding +3.8%/yr from FY2021.

Key figures

Market cap HK$1.0B (≈ $133M) Micro · P/E ratio 8.2 · P/S ratio 0.87 · Dividend yield 1.6% · Net margin 10.6% · Return on equity 8.5% · Return on assets (EBIT) 8.9% (5-year average) · Operating margin 16.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 132%, 2566 screens cheaper than that median.

Fair Value models

Bear HK$7.73 Fair Value HK$9.90 Bull HK$11.96
Price HK$4.26 · Upside +132.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$6.69 HK$7.95 HK$9.96 79
Growth DCF HK$6.80 HK$7.99 HK$9.73 77
Owner Earnings HK$6.55 HK$7.78 HK$9.73 75
All 24 models by family
DCF Models
FCF DCF HK$6.69 HK$7.95 HK$9.96 79
Owner Earnings HK$6.55 HK$7.78 HK$9.73 75
5Y Revenue Exit HK$7.55 HK$10.27 HK$14.23 70
5Y EBITDA Exit HK$8.83 HK$12.48 HK$17.32 72
5Y P/E Exit HK$8.96 HK$12.71 HK$17.18 68
10Y Revenue Exit HK$6.96 HK$8.66 HK$10.47 65
10Y EBITDA Exit HK$7.73 HK$9.79 HK$11.96 67
10Y P/E Exit HK$7.80 HK$9.90 HK$11.89 62
Earnings-Based
Graham-Dodd HK$4.67 HK$5.70 HK$6.42 65
EPV HK$5.88 HK$6.38 HK$6.78 71
Dividend Discount
Gordon GGM HK$0.4500 HK$0.4800 HK$0.5200 67
DDM Multi-Stage HK$0.4500 HK$0.5100 HK$0.5900 65
Multiples
P/E Multiple HK$11.32 HK$15.10 HK$18.87 63
P/S Multiple HK$8.75 HK$11.67 HK$14.58 58
P/B Multiple HK$24.09 HK$32.12 HK$40.15 55
EV/EBIT HK$10.21 HK$13.73 HK$17.26 66
EV/EBITDA HK$10.67 HK$14.34 HK$18.02 67
EV/Revenue HK$7.19 HK$10.42 HK$13.65 53
Asset-Based
NCAV (Graham) HK$3.32 HK$5.02 HK$6.28 54
Growth DCF
Growth DCF HK$6.80 HK$7.99 HK$9.73 77
Rev-Margin DCF HK$7.55 HK$10.42 HK$13.95 70
Economic Profit
Residual Income HK$6.20 HK$6.51 HK$7.02 73
ROIC Compounder HK$5.88 HK$6.38 HK$6.78 69
Growth Earnings
Growth-Adj P/E HK$7.98 HK$11.40 HK$14.82 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 60/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 54
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 64
Do the profits arrive as real cash?
Financial strength 90
Debt, balance sheet and risk of trouble
Investment 22
Does it invest with discipline instead of growing at any price?
Low Volatility 22
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 95
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+4.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.0%
Dividend (yield on the price)1.6%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 13%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−27.3%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −28.5% a year for the price.

Watch 2566, get fair value alerts →

Compare Hangzhou Jiuyuan Gene with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 60 · Top 25%
Fair Value upside +132.4% · Top 25%
Profitability
Return on equity (12 months) 8.5% · Top 25%
Return on assets 6.5% · Top 25%
Net margin (12 months) 10.7% · Above median
Operating margin (12 months) 16.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −1.2% · Below median
Dividend yield (12 months) 1.6% · Above median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 8.2× · Cheapest 25%
P/B 0.54× · Cheapest 25%
P/S (12 months) 0.68× · Cheapest 25%
Price / free cash flow (fiscal year) 5.9× · Cheapest 25%
EV/EBITDA 3.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)34 · sector 0
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)31 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2566
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs 2566
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2566
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2566
argenx SE ARGX $960.04 $908.40 −5% vs 2566
CSL Limited CSL A$202.92 A$185.51 −9% vs 2566
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2566
Roivant Sciences Ltd ROIV $39.53 $19.47 −51% vs 2566
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2566
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2566

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hangzhou Jiuyuan Gene: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hangzhou Jiuyuan Gene Fair Value". https://www.fairvalue-calculator.com/stock/2566

Frequently asked questions

Is Hangzhou Jiuyuan Gene (2566) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$9.90 versus a price of HK$4.26, about +132% upside (undervalued).
What is the fair value of 2566?
Our model-based fair value for Hangzhou Jiuyuan Gene is HK$9.90 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$4.26.
What is the quality score of 2566?
Hangzhou Jiuyuan Gene has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Jiuyuan Gene (2566)?
Our model-based price target is the fair value of HK$9.90 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario HK$7.73, optimistic scenario HK$11.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Jiuyuan Gene stock forecast for 2026?
Our models put fair value at HK$9.90, about +132% upside versus a price of HK$4.26 (undervalued). Cautious scenario HK$7.73, optimistic scenario HK$11.96. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Jiuyuan Gene (2566)?
Hangzhou Jiuyuan Gene reported trailing-twelve-month revenue of about 1.3B CNY (latest available figure, as of Nov 14, 2026).
Does Hangzhou Jiuyuan Gene pay a dividend?
Hangzhou Jiuyuan Gene currently shows a dividend yield of 1.57% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Hangzhou Jiuyuan Gene (2566) and when is the ex-dividend date?
Hangzhou Jiuyuan Gene pays a dividend of HK$0.067 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Jun 17, 2026. The payout ratio is 9.8% of earnings. Free cash flow covers the dividend 11.11 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Hangzhou Jiuyuan Gene (2566)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at Hangzhou Jiuyuan Gene shrinks by 27.3 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew 0.0 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 2566 use?
Our models discount Hangzhou Jiuyuan Gene at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hangzhou Jiuyuan Gene that is -27.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Hangzhou Jiuyuan Gene (2566) delivered so far?
Over the past 4 years revenue at Hangzhou Jiuyuan Gene grew 0.0 % a year. The price currently implies free-cash-flow growth of -27.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hangzhou Jiuyuan Gene (2566) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Hangzhou Jiuyuan Gene (-27.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hangzhou Jiuyuan Gene (2566)?
The free-cash-flow yield on the price is 17.23 %: that much free cash flow Hangzhou Jiuyuan Gene produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hangzhou Jiuyuan Gene (2566)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Jiuyuan Gene it is HK$9.90 per share (as of Nov 14, 2026), against a price of HK$4.26. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hangzhou Jiuyuan Gene stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 2566 trades below its calculated fair value: price HK$4.26, fair value HK$9.90, a gap of about +132% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2566?
No. The price is what the market pays today (HK$4.26); the fair value is what the company's own numbers justify (HK$9.90). For Hangzhou Jiuyuan Gene the two are HK$5.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Jiuyuan Gene worth?
The market values Hangzhou Jiuyuan Gene at about HK$1.0B (market capitalisation, as of Nov 14, 2026). Per share that is HK$4.26; our models calculate a fair value of HK$9.90 per share.
What do the bullish and bearish scenarios say about 2566?
Our models span a range for Hangzhou Jiuyuan Gene: cautious scenario HK$7.73, base HK$9.90, optimistic HK$11.96 per share (as of Nov 14, 2026, price HK$4.26). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2566?
Hangzhou Jiuyuan Gene trades at a price-to-earnings ratio of 8.2 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$9.90 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.7, EV/EBITDA 3.2.
How solid is the balance sheet of Hangzhou Jiuyuan Gene (2566)?
Balance-sheet figures for Hangzhou Jiuyuan Gene (as of Nov 14, 2026): return on equity 8.5%, debt of 0.04 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 2566 from its 52-week high?
Hangzhou Jiuyuan Gene trades at HK$4.26, about 59% below its 52-week high of HK$10.46 and at the low of HK$4.26 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$9.90 is for.
Which stocks are comparable to Hangzhou Jiuyuan Gene?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Jiuyuan Gene stock attractive at the current price?
The data as of Nov 14, 2026: price HK$4.26, calculated fair value HK$9.90 (+132%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2566 calculated?
We run Hangzhou Jiuyuan Gene through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$9.90 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Hangzhou Jiuyuan Gene currently trades 57% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Jiuyuan Gene (2566)?
The closing price on Nov 13, 2026 was HK$4.26. Our model-based fair value is HK$9.90, about +132% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Jiuyuan Gene right now?
The price is below even our cautious bear case (HK$7.73). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Hangzhou Jiuyuan Gene

How large is the market capitalisation of Hangzhou Jiuyuan Gene (2566)?
The market capitalisation of Hangzhou Jiuyuan Gene is HK$1.0B (≈ $133M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Jiuyuan Gene (2566)?
The price-to-sales ratio of Hangzhou Jiuyuan Gene is 0.87 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Hangzhou Jiuyuan Gene (2566)?
The dividend yield of Hangzhou Jiuyuan Gene is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Jiuyuan Gene (2566)?
The net margin of Hangzhou Jiuyuan Gene is 10.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Jiuyuan Gene (2566)?
The return on equity (ROE) of Hangzhou Jiuyuan Gene is 8.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Jiuyuan Gene (2566)?
On an EBIT basis the return on assets of Hangzhou Jiuyuan Gene is 8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Jiuyuan Gene (2566)?
The operating margin of Hangzhou Jiuyuan Gene is 16.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Jiuyuan Gene (2566)?
Revenue at Hangzhou Jiuyuan Gene is down 1.2% versus a year earlier (3y avg +5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Jiuyuan Gene (2566)?
Earnings per share at Hangzhou Jiuyuan Gene are growing 2.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hangzhou Jiuyuan Gene (2566) carry?
The net debt of Hangzhou Jiuyuan Gene is 72.2M CNY (fiscal year 2023, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hangzhou Jiuyuan Gene in the live analysis

One click puts Hangzhou Jiuyuan Gene on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.